Attend Discovery & Development US

A surge of innovation is breaking across drug discovery & development – are you ready to be a part of this opportunity? Do you have the knowledge, tools and connections in place to accelerate your pipeline?
Discovery & Development US provides the perfect platform for you to benchmark against industry leaders in the drug discovery community. Through our events and channels, we enable you to connect with the right scientific experts & product developers to focus on solving challenges together.
We’re an established movement for the whole drug development chain, empowering over 30,000 leaders across the USA (change figure?).
Discovery & Development, the second event of the year, is taking place on the 2 – 3 October in San Diego, CA. Running for 2 full days across 3 dedicated programmes, this event promises an exclusive forum to identify high-potential targets, discovery and development technologies, and establish successful collaborations and partnerships.

1000

leading pharma, biotech, regulatory & academic delegates

700

pre-arranged 1-2-1 meetings, facilitating business growth

hours of presentations, discussions & interactive content

hours of networking breaks, including fireside chats & refreshments

Be part of the breakthrough
Our events are where next-generation drugs emerge.
Connect with the scientists, innovators and decision-makers shaping the future of drug discovery and development.

Survey the competitive landscape
Get a comprehensive view of the translational pipeline — from early discovery to clinical development.
Benchmark your progress against peers and stay ahead of emerging trends.

Join the conversation
Engage with fellow researchers and industry experts.
Dive into cross-disciplinary discussions on novel modalities, targets, platforms and regulatory challenges.

Bridge your knowledge gaps
Deepen your expertise with insights from leading specialists.
We cover the full small molecule & biologics spectrum — from discovery to formulation & delivery.

Accelerate your work
Explore how AI, data science and automation are transforming R&D.
Identify the tools and platforms poised to de-risk programs, shorten timelines, and enhance decision-making.

Build partnerships that last
Meet the collaborators your pipeline needs — from discovery partners to CROs, CDMOs and academic labs.
Find alignment, foster innovation, and forge relationships that move science forward.

Networking & knowledge-sharing is at the heart of what we do, with 400+ pre-arranged 1-2-1 meetings and over 11 hours of networking - don't miss the opportunity to connect with 1,000 leaders from across pharma, biotech and academia.

Engaging Thought Leadership
Experience over 150 industry talks, interactive discussions, and collaborative roundtables, with insights from industry leaders to benchmark your research & development pipeline.

Global Technology Showcase
An international exhibition showcasing cutting-edge technologies and services from premier providers in the scientific field.

Networking Emphasis
Unparalleled networking opportunities, including personalised 1-2-1 meetings, a start-up zone, vibrant drinks reception, gala dinner, and informal gatherings to foster meaningful connections.

Gala Dinner
Prepare for an exclusive evening at [venue], where you’ll enjoy a sumptuous three-course meal, engaging networking activities, and surprise entertainment—all set against an enchanting backdrop that seamlessly blends the wonders of science with sophisticated elegance.

Start-up Zone & Early-Stage R&D Innovation Programme
Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging start-up companies & talks from investors and collaborators to foster early-stage partnerships.

Panel Discussion: Technological Advancements For Novel Target Discovery

Application of new technologies in identifying therapeutics for novel or currently undruggable targets
Utilising AI/ML
Challenges & future opportunities

Panellists include Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech, Ian Roberts, Senior Director, Digital Biology, Healx & Zoran Rankovic, Director, Center for Protein Degradation, The Institute of Cancer Research

Panel Discussion: Novel Platforms & Techniques To Improve Hit Identification

• Optimising Hit discovery
• Minimising false positives
• Integration of techniques

Moderated by Jonathan Hopper, Vice President Platforms & Founder, OMass Therapeutics

Panel Discussion: Fostering Partnerships & Collaboration In 2025 – as part of our newly introduced Early-Stage R&D Innovation Programme

Emerging technologies & techniques
Cross-sector partnership
Open innovation

Moderated by Alexander Natz, Secretary General, EUCOPE & panellists from Cicio Holdings, BioAge Labs, European Commission, Pfizer & Business Region Gothenburg

Panel Discussion: Breakthrough Biotech: How Research Leaders Fund The Next Big Idea

How research leaders identify and support fundable biotech innovations
Overcoming early-stage funding gaps in biotech startups
The role of research partnerships with pharma, VCs, and industry in startup success
What startups can learn from research-backed biotech wins

Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch; David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc; David Dexter, Director of Research, Parkinsons UK

Fireside Chat: Impact of AI & Big Data in Drug Discovery & Development

Panel Discussion: Translational Studies to Support Better Drug Design

Bridging the gap between pre-clinical & clinical research
Biomarkers & AI/ML in translational research

Moderated by Philippe Marc, Executive Director, Global Head of Integrated Data Sciences, Novartis

Panel Discussion: Fostering Collaboration To Accelerate Neurodegenerative Disease Research

• Pharma, biotech & academic partnerships
• The need for innovation, data & technology in CNS research
• Challenges to be solved through collaboration

Moderated by Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford. Panellists include Knut Biber, Research Fellow & Head of Glial Biology Team, AbbVie; Sarah Jolly, Principal Scientist, LifeArc; Michael Johnson, Professor of Neurology & Genomic Medicine, Imperial College London

Day 2 Breakfast Workshop - LifeArc: Biomarkers In Neurodegenerative Diseases: From Detection To Progression - Are Blood -Based Biomarkers Enough?

Beyond blood-based biomarkers?
Are we any closer to a solution?
Application of AI/ML

Moderated by Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc

Panel Discussion:
Automation & Robotics In Drug Discovery & Development – Where Are We Now?

• Impact of automation
• AI/ML
• Robotics in lab processes

Moderated by Rekha Lakshmanan, Global Head of Data Office, AstraZeneca

Panellists include: James Love, Vice President Cross Modalities Workflows, Novo Nordisk, Sarah Trice, COO & Head of US Operations, XtalPi & Tom Kissling, pRED Lab Automation Partner, Roche

Day 2 Breakfast Workshop: SiLA & AnIML Splash

• Splash! Is a unique event for every digital lab enthusiast. It combines an educational part with a hands-on session to try out standards in action. Pick up the details on the popular SiLA and AnIML standards, understand how they work and where you can put them to use. Our hands-on session lets you experience the standards in action firsthand. We’re bringing real and cloud-based instruments and lots of example data sets
• Feel free to bring an instrument or your own data

Panel Discussion: Moving Beyond Oral Delivery

• Nanoparticles
• Inhalation
• Transdermal
• Developments with Oral Delivery

Moderated by Sandor Batkai, Life Science Consultant, Former, Head of Medical Research and Intelligence, Cardior Pharmaceuticals

Panellists include Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group, Joël Richard, Executive Head, Product Development, DBV, Kamalinder Singh, Professor of Pharmaceutical, Technology & Drug Delivery, Karsten Mäder, Professor, Martin Luter University Halle-Wittenberg

Panel Discussion: AI/ML & Novel Technologies In Formulation & Delivery

Applications of AI/ML in formulation and delivery
AI-driven approaches to optimise dosage forms
Novel delivery technologies
AI/ML for personalised formulations

Moderated by Shilpa Thosar, CMC/Regulatory CMC Executive, Former Executive Director, Cara Therapeutics

Roundtable: Discovery And Delivery Of Therapeutics Across The Blood Brain Barrier – Where Are We Now?

Brain shuttle platform
Monocytes
Microbubbles

Moderated by Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group

Meet Our Expert Speakers

Discovery & Development Europe 2025 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Andreas Gryczke

Director, Process Engineering,

AbbVie

Banurekha Lakshmanan

Global Head of Data Office,

AstraZeneca

Emma Mead

Chief Scientific Officer, Oxford Drug Discovery Institute,

University of Oxford

Heinrich Haas

Chief Technology Officer,

Neovacs

Karin Conde-Knape

Senior Vice President,

NovoNordisk

Morten Grunnet

Vice President, Head of Neuroscience ,

Lundbeck

Philippe Marc

Executive Director, Global Head of Integrated Data Sciences,

Novartis

Shadi Farhangrazi

Chief Executive Officer,

S.M. Discovery Group

Sorina Morar-Mitrica

Director,

Novartis

Stephen Pham

Senior Vice President, Product Development,

Avalyn Pharma Inc.

Ulrich Betz

Senior Vice President Innovation,

Merck

Show More Speakers

Hide Speakers

Aaron Smith

Associate Director,

AstraZeneca

Abhishek Choudhary

Principal Data Engineer,

Bayer

Abi Heath

Patent Attorney & Counsel,

Kilburn & Strode

Alain Martelli

External Science Lead Europe, Discovery Network,

Pfizer

Amal Ali Elkordy

Professor,

University of Sunderland

Amardeep Singh Bhalla

Executive Director,

Regeneron

Andreas Bernkop Schnurch

Professor,

University of Innsbruck

Andreea Apostol

Operations Lead,

Pfizer Ltd

Andrew Woodhead

Head of Chemistry,

Astex Pharmaceuticals

Andy Pike

Director,

AstraZeneca

Anna-Pia Papageorgiou

Health Innovations & Ecosystems,

European Commission

Antonia Stepan

Section Head,

Roche

April Woulfe

Scientist,

Alchemab Theraputics Ltd

Arianna Sabò

Head of Research & Discovery,

QUANTRO Therapeutics

Arne Skerra

Professor ,

Technische Universität München

Benedict Cross

CTO,

PhoreMost Ltd

Burkhard Schäfer

Managing Director & Director at SiLA,

SiLA

Cesare Spadoni

Co-Founder & Chief Operating Officer,

Oncoheroes Biosciences

Christine Maurer

Scientific Associate Director Biotransformation,

Merck & Cie KmG

Christoph Rösli

Director Research,

CSL Behring & BaseLaunch

Chuang Kee Ong

Director Data Product,

GSK

Cornelis Van Tilburg

Head of KiTZ CTU,

Hopp-Kindertumorzentrum Heidelberg

Covadonga Paneda

Chief Operating Officer,

Altamira Therapeutics

Daniel Tondera

Head of Biology,

Pantherna Therapeutics

David Jenkinson

Head of Childhood Cancer Translational Challenge,

LifeArc

David Dexter

Research Director,

Parkinson's UK

David Gnutt

Vice President, Complex In Vitro Lead, RED Cardiovascular, Renal and Immunology, ,

Bayer

Davide Gianni

Senior Director,

AstraZeneca

Delphine Heenen

Chief Managing Director,

KickCancer

Diana Knapp-Bühle

Associate Director and DMPK Lead,

Merck Healthcare KGaA

Duane Schulthess

Chief Executive Officer,

Vital Transformation

Eric Lorent

Senior Scientist,

Sanofi

Eva Aparicio

Product Owner,

Roche

Fabrizio Dissegna

Formulator,

Chiesi

Farshad Ramazani

Senior Expert Science & Technology ,

Novartis

Florian Ries

Senior Scientist,

AbbVie

Gergely Toth

Chief Executive & Scientific Officer,

Cantabio Pharmaceuticals

Giovanni Spagnolli

Chief Technology Officer,

Sibylla Biotech

Giovanni Ca'Zorzi

Strategic Communications,

Cohesion Bureau

Heena Khatter

Principal Scientist,

Roche

Heide Düvel

Scientific Associate Director,

Merck Healthcare KGaA

Hemachandran Kannan

Director of the AI Centre,

Woxsen University

Ian Roberts

Senior Director, Digital Biology,

Healx

Iris Valtingojer

Lead,

Sanofi

Jack Doolan

Investigator,

GSK

James Dale

Director of Chemistry,

PharmEnable Therapeutics

James Love

Vice President, Cross Modalities Workflows,

Novo Nordisk

James Connell

Scientific Director - Translational Matrix Group,

LifeArc

Jens Twellmeyer

Associate Director,

Novartis AG

Jitendra Kumar

Lead Scientist,

Entos Pharmaceuticals US

Joao Seixas

CEO,

TargTex

Joël Richard

Executive Head,

Enterome

Johanna Roostalu

Director, Therapeutics, Venture Creation,

BioInnovation Institute

Jonathan Hopper

Vice President,

OMass Therapeutics

Jörg Berghausen

Associate Director,

Novartis

Jose-Carlos Gomez-Tamayo

Scientist,

Janssen Pharmaceutical Companies of Johnson & Johnson

Kamalinder Singh

Professor,

University of Central Lancashire

Karsten Maeder

Professor,

Martin Luther University Halle-Wittenberg

Katja Petkau Milroy

Formulation Scientiest,

Microsol

Kelly Zalocusky

Senior Director of Computational Biology, Neuroscience ,

Recursion Pharmaceuticals

Knut Biber

Research Fellow & Head of Glial Biology Team,

AbbVie

Konstantinos Gkatzis

Team Lead,

Ksilink

Kristina Levan

Business Developer,

Business Region Gothenburg

Krisztian Kaszas

Principal Scientist,

Johnson & Johnson

Lars van der Veen

Chief Scientific Officer,

ionctura

Laura Gasparini

Director -Tau pathobiology,

AbbVie

Lene Gerlach

Founder,

Hadean Ventures

Lubor Gaal

Chief Financial Officer & Chief Business Officer,

Circio

Maeve Caldwell

Professor,

Trinity College Dublin

Manuela Cerina

Scientific Director of Neurodegeneration,

LifeArc

Marcos Costa

Principal Scientist,

Roche

Maria Levitin

Director,

Grünenthal GmbH

Marie-Christine Pardon

Assistant Professor in Translational Neuroscience,

University of Nottingham

Marius Lutz

Scientist, High-Throughput Experimentation, Chemical Reaction Screening,

Hoffmann La Roche Ltd

Mark Chiu

Chief Scientific Officer,

Tavotek BioTherapeutics

Markus Hierl

Principal Associate,

Hoffmann La Roche Ltd

Martinus Capelle

Scientific Director,

Johnson & Johnson

Meike Harms

Lead Scientist,

Merck

Meiling Li

Technical project leader,

Roche

Michael Johnson

Professor of Neurology and Genomic Medicine,

Imperial College London

Michele Cleary

President & Chief Scientific Officer,

Advancium Health Network

Miraz Rahman

Professor of Medicinal Chemistry,

King's College London

Miroslav Cik

Senior Principal Research Scientist,

Abbvie

Moein Moghimi

Professor,

Newcastle University

Naisha Shah

Vice President of Data Science,

BioAge Labs

Peng Leong

CBO and Head of Brain Aging,

Bioage labs

Phil Noble

Head of Single B Cell Antibody Discovery,

UCB Pharma

Philip Hewitt

Global Head of Early Investigative Toxicology,

Merck

Rainer Wilcken

Director, Computational Chemistry,

Flare Therapeutics Inc

Ramesh Kashi Kashi

Senior Scientific Advisor,

EPOK Therapeutics

Rick Ewing

Vice President,

Rapafusyn Pharmaceuticals

Robin Loving

Chief Scientific Officer,

Salipro Biotech AB

Roderick Beijersbergen

Head,

The Netherlands Cancer Institute

Sabine Kuratli

Chemistry, Manufacturing and Control Lead,

CEPI

Sagar Chandekar

Senior Medical Director, Alzheimer's Disease,

Novo Nordisk

Sam Daems

Portfolio Principal,

Waterland Private Equity

Sandor Batkai

Freelance Consultant,

Formerly Cardior Pharmaceuticals

Sarah Jolly

Principal Scientist,

LifeArc

Shreenivasa Rajanala

Vice President,

Bayer

Simone Hornemann

Director UZH CRISPR Screening Hub,

University of Zurich

Sonja Kühn

Head,

LES LABORATOIRES SERVIER

Sophie Janbon

Director,

AstraZeneca

Steen Krogsgaard

Scientific Automation Director,

Novo Nordisk

Stefan Schiesser

Director,

AstraZeneca

Stefano Romanelli

Senior Government Affairs Manager,

EUCOPE

Stephanie Harlfinger

Senior Director, Global Head NCE DMPK,

Merck & Cie KmG

Supriyadi Hafiz

Senior Scientist,

Merck

Suruchi Vishwasrao

Senior Scientist,

Merck Life Science Pvt. Ltd.

Sven Verguts

Associate Director, Emerging Biotech & ATMPs,

Merck

Tamara Maes

Former Chief Scientific Officer & Founder,

Oryzon Genomics

Tanvir Tabish

Director,

Boehringer Ingelheim

Tatiana Marcozzi

Senior Scientist,

Janssen

Thanneer Malai Perumal

Senior Principal Scientist,

Hoffmann La Roche Ltd

Thomas Von Erlach

Chief Scientific Officer,

Vivtex

Tjasa Vrlinic

Principal Investigator,

Medincell

Tom Kissling

pRED Automation Partner & Director at SiLA,

F. Hoffmann-La Roche AG

Tomasz Ratajczak

Formulation Expert,

Polpharma

Toria Legh-Land

Computational Pharmaceutics Lead,

Microsol

Trond Ulven

Professor,

Copenhagen University

Valentina Romeo

Principal Scientist & Group Leader,

Roche

Varun Kushwah

Senior Research Scientist,

Central Drug Research Institute

Vik Reebye

Head,

MiNA Therapeutics

Virginia Ballotta

New Ventures Manager,

BaseLaunch

Vladimir Talibov

Associate Principal Scientist,

Sprint Bioscience

Yi Sun

Associate Professor,

Technical University of Denmark

Zeeshan Ahmad

Reader in Pharmaceutics and Drug Delivery,

University of Manchester

Zhi Yao

Principal Scientist,

LifeArc

Zhizhou Fang

Associate Scientific Director,

Merck Healthcare KGaA

Zoran Rankovic

Director,

St Jude Children's Research Hospital

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow; and Lundbeck Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Roundtable: Regulatory Insights On Bringing A Peptide To Human Trials

Moderator: Paul Reid, Co-Founder & Chief Scientific Officer, Celtic Bio

Oligonucleotides
Workshop: Development Of Targeted Delivery Systems

Two Presentations, followed by a Panel Discussion on 'The Next Chapter Of Oligonucleotide Delivery'
Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies?

Presented by: Daniel Larocque, Innovation Lead, Innovation and Emerging Science, Sanofi

Anna Perdrix

CEO,

Sixfold Bioscience

Fernando Albericio

Professor,

University of KwaZulu-Natal

Kelly Loyet

Distinguished Scientist,

Genentech

Kevin Fitzgerald

Chief Scientific Officer,

Epsilogen

Livija Deban

Chief Scientific Officer,

Prokarium

Maria Koufali

Director,

UK Vaccine Innovation Pathway

Marta Amaral

Head High Throughput Protein Engineering in Large Molecules Research,

Sanofi

Nazneen Dewji

Chief Executive Officer,

Cenna Biosciences

Philip Beer

CSO,

Step Pharma

Rick Hibbert

Vice President & Head of CMC Science & Technologies,

Genmab

Sudhir Agrawal

President & Founder & Affiliate Professor ,

ARNAY Sciences & UMass Chan Medical School

Tristan Vaughan

Vice President Protein Engineering,

Immunocore

Aaron John Balana

Scientist III,

Genentech

Aikaterini Gatsiou

Assistant Professor,

Lancaster University

Alain Wagner

Research Director,

Strasbourg University

Alastair Lawson

Vice President,

UCB

Alessandra Tolomelli

Associate Professor,

University of Bologna

Alessandro Gori

Group Leader,

National Research Council of Italy

Alexandria Cogdill

Head of Strategic Initiatives, Global Business Development,

Daiichi Sankyo, Inc

Álvaro Enríquez García

Medicinal Chemist,

Eli Lilly

Amita Vaidya

Principal Scientist,

Sanofi

Ammar Ahmed

Senior Scientist,

Imperial College London

Amy Li

Director, Drug Discovery,

T-Therapeutics Ltd

Anand Kumar

Senior Scientist,

Sanofi

Andreas Reichel

Vice President, Head of Research Pharmacokinetics,

Bayer

Andreas Midbøe Hoff

Head of In Silico & AI Department,

Nykode

Andrew Slee

Chief Operating Officer,

AgenusBio

Andrew Jamieson

Professor Of Chemical Biology ,

University of Glasgow

Andrew Buchanan

Principal Scientist: Biologics Engineering,

AstraZeneca

Andrew Creese

Associate Director,

Immunocore

Andri Vasou

Head of Platform Development,

Bioarchitech

Aneesh Karatt Vellatt

Chief Scientific Officer,

Maxion Therapeutics

Anna Hine

Professor of Protein Engineering,

Aston University

Anna Maria Papini

Full Professor and Group Leader of PeptLab,

University of Florence

Annelise Vuidepot

Chief Technology Officer,

Immunocore

Antonio Postigo

Chief Scientific Officer,

Stratosvir

Aswin Doekhie

Chief Technology Officer,

EnsiliTech

Baldur Sveinbjørnsson

Chief Scientific Officer,

Lytix Biopharma

Bassam Hallis

Deputy Director of Research and Evaluation,

UK Health Security Agency

Benjamin Lindner

Data Scientist,

Boehringer Ingelheim RCV GmbH & Co KG

Berit Olsen Krogh

Senior Research Fellow,

Lundbeck

Bernard Maillere

Head of Laboratory,

CEA

Bjorn Onfelt

Professor of Applied Physics,

Royal Institute of Technology

Brian Schanen

Global Head of Biomarkers,

Sanofi

Caleb McClain

Chief Executive Officer,

ANUNA (AI+BIO)

Callum Scott

Head of Development,

Scancell

Carla Vinals

Vice President, Global Regulatory Product Strategy,

Moderna Therapeutics

Carol Sze Ki Leung

Principal Investigator ,

Ludwig Institute, Oxford University

Charlotte Vernhes

Scientific and Medical Affairs Director,

Vaccines Europe

Christian Garde

Director,

Evaxion Biotech

Christopher Scott

Professor,

Queen's University Belfast

Dan Hardy

CEO,

Microsol

Daniel Larocque

Innovation Lead, Innovation and Emerging Science,

Sanofi Vaccines

Daniel Fonseca

Senior Research Scientist I ‑ Experimental Immunology,

Immunocore

Daniel Sejer Pedersen

Chemical Development Specialist,

Novo Nordisk A/S

David Craik

Professor,

The University of Queensland

David Brockwell

Professor,

University of Leeds

David Pejoski

Co-founder, Co-Chief Executive Officer, Chief Operating Officer, & Board Member,

Adoram Therapeutics

David Wraith

Professor,

UNIVERSITY OF BIRMINGHAM

Denise Steckel

Head of Clinical Collaborations Development,

Genentech

Deniz Eris

Principal Scientist,

Novartis

Dorothy Bray

Senior Executive,

Celtic Biotech

Ed Tate

Professor,

Imperial College London

Eef Dirksen

Director Analytical Development & Quality Control,

Byondis B.V.

Elisa Marelli

Research Scientist,

Scancell

Elizabeth Boulter

Senior Scientist,

AstraZeneca

Erik Vernet

Vice President - Scientific Data Registration,

Novo Nordisk

Ernst Weber

Head of Molecular Design & Engineering & Bayer Science Fellow,

Bayer AG

Etienne Matous

Head of Lead Optimisation,

Iginnovate

Fazel Shabanpoor

Lab Head Peptide And Oligonucleotide Therapeutics,

The Florey Institute of Neuroscience and Mental Health

Felix Schumacher

Program Leader Targeted Therapeutics,

Roche

Francisca Wollerton

Senior Director,

AstraZeneca

Gabriel Wong

Senior Director Physician, Clinical Research, Immunology,

AstraZeneca

Georgios Skretas

Director,

Biomedical Sciences Research Center "Alexander Fleming"

Giulio Russo

Senior Scientist,

Merus

Hans Melo

Chief Executive Officer,

Menten Biotechnology Labs

Hans Van Der Vliet

Chief Scientific Officer,

LAVA Therapeutics

Helen Bright

Chief Scientific Officer,

Centauri Therapeutics

Helene Kaplon

Translational Scientist,

Servier

Henry Maun

Staff Scientist,

Genentech

Hester Van Zeeburg

Project Manager Immune & Disease Monitoring,

Mendus AB

Ian Hamley

Professor of Physical Chemistry,

University of Reading

Ijeoma Uchegbu

Professor of Pharmaceutical Nanoscience,

University College London

Immanuel Lerner

Chief Executive Officer,

Pepticom

Isabelle Sermadiras

Associate Principal Scientist,

AstraZeneca

Itishri Sahu

Program Lead Therapeutics,

Ziphius Vaccines

Iulia Oita

CMC Manager,

Ziphius Vaccines

Janos Tibor Kodra

Principal Scientist,

Novo Nordisk

Jean Ge

Patent Attorney,

Wolf Greenfield

Jennifer Percival-Alwyn

Scientific Leader,

GSK

John Maher

Chief Scientific Officer,

Leucid Bio

Jonathan Kwok

Chief Executive Officer,

Infinitopes

Joost Uitdehaag

Head of Biology,

Crossfire Oncology

Jörg Wischhusen

Professor,

University Hospital Würzburg

Jutta Eichler

Professor Medicinal Chemistry,

University of Erlangen-Nurnberg

Karen Silence

Head Preclinical Product Development,

Argenx BVBA

Kate Smith

Senior Director, Head of UK Protein and Cell Sciences,

GSK

Ken Chow

Health Tech Counsel,

Flanders Investment & Trade

Kerry Chester

Professor of Molecular Medicine, Research Department of Oncology - University College London, Director at The Antibody Society,

The Antibody Society

Kevin Maskell

Research Director,

Bioarchitech

Knud Jørgen Jensen

Professor,

Copenhagen University

Kuda Muchandibaya

Lecturer for Supply Chain Management & Logistics,

Rhine-Waal University of Applied Sciences

Laura Starkie

Director,

UCB

Laura Collins

Director Bioinformatics,

Immunocore

Leonardo De Maria

Principal Scientist,

AstraZeneca

Louis Diorazio

Senior Principal Scientist,

AstraZeneca

Lucia Ferrazzano

Junior Assistant Professor,

University of Bologna

Lukas Pekar

Lab Head,

Merck

Mads Hald Andersen

Professor,

National Centre For Cancer Immune Therapy (CCIT-dk)

Mani Mudaliar

Director, Quantitative Biomarkers,

Recursion

Marc Vendrell

Professor of Translational Chemistry,

University of Edinburgh

Maria Fawaz

Associate Principal Scientist,

MSD

Marie McAvoy

Chief Scientific Officer,

Nanosyrinx

Marina Fedorova

Scientific Investigator,

GSK

Mark Eccleston

Chief Executive Officer,

ValiRx Plc.

Markus Templin

Head Of Cellular & Molecular Biology,

NMI

Martina Ochs

Project Leader,

CEPI

Mathieu Cinier

Scientific Director,

Affilogic

Matthew Burrell

Associate Director,

AstraZeneca

Mattias Malm

Senior Scientist,

Ferring Pharmaceuticals

Micaela Graglia

Analytical Chemist, Molecular Design,

Silence Therapeutics

Michael Delaney

Principal Scientist,

Novo Nordisk

Mihaela Bozic

Scientist,

T-Therapeutics

Mikhail Kuravskiy

Principal Scientist,

UCB

Nathan Alves

Research Director,

Indiana University School of Medicine

Nesrine Chakroun

Associate Director,

Merus NV

Nicola Ferrari

Director,

AstraZeneca

Norbert Furtmann

Head of AI Innovation NANOBODY® Platform,

Sanofi

Obinna Ubah

Principal Scientist,

Elasmogen Limited

Owen Vickery

Associate Principal Scientist,

AstraZeneca

Patricia Alves

Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,

Instituto de Biologia Experimental e Tecnológica

Paul Wassmann

Senior Principal Scientist,

Novartis AG

Pawel Stocki

Vice President,

Ossianix

Peter Sondermann

Chief Executive Officer,

Tacalyx GmbH Privacy Policy Imprint

Prasun Chakraborty

Chief Executive Officer and Founder,

Genevation LTD

RaJ Mehta

CEO,

Adendra Therapeutics

Raymond Tesi

President & Chief Executive Officer,

InMune Bio

Reeta Daswani

Senior Scientist II,

Sixfold Biosciences

Rita Martello

Scientific Director, NBE DMPK Lead,

Merck KGaA

Robert Andrews

Biotech IP Strategist,

Mewburn Ellis LLP

Rodrigo Abreu

Principal Scientist,

LifeArc

Russell LaMontagne

CEO,

BITT

Sagar Kathuria

Sr. Scientist, Protein Engineering I,

Sanofi

Sandor Batkai

Freelance Consultant,

Batkai.Condulting (ex-Cardior Pharmaceuticals)

Sandra Tremmel

Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,

Roche

Sandrien Janssens

CMC Director,

Mosanna Therapeutics

Santiago Parpal

Principal Scientist,

Sprint Bioscience

Sarah Stuart

High Throughput Characterisation Team Leader,

GSK

Sarah Hindson

Senior Scientist,

GSK

Saurabh Sen

Associate Director, Cell Line Development, Mammalian Platform Biologics,

Sanofi

Sebastian Sten

Associate Principal Scientist,

AstraZeneca

Sevim Ozgur Bruderle

Lab Head,

Sanofi

Shao-An Xue

Senior Scientist,

University College London

Silvia Crescioli

Business Intelligence Creator,

The Antibody Society

Simon Hufton

Section Head Molecular Immunology, Division of Biotherapeutics,

MHRA

Simone Friedrich

Director Antibody Discovery & Development,

iOmx Therapeutics

Sonia Macia

Chief Medical Officer,

Aromics Therapeutics

Sonja Merkas

Founder, Creator & Doer,

Livinovea

Sophia Karagiannis

Professor of Translational Cancer Immunology and Immunotherapy,

King's College London

Sritama Bose

Head of Chemistry Research and Innovation,

NATA

Stefan Zielonka

Senior Director, Global Head of Antibody Discovery & Protein Engineering,

Merck KGaA

Stephen Miller

Principal Scientist,

Genentech

Steve Hood

Senior Director, Oligonucleotide ADME Strategy, DMPK,

GSK

Steven Schmitt

Co-Founder & Chief Executive Officer,

Myria Biosciences

Stine Friis Thorsen

Director Clinical Development,

Evaxion Biotech

Sue Charlton

Head of Clinical Evaluation,

UKHSA

Talip Ucar

Sr. Director,

AstraZeneca

Tatyana Ponomaryov

Principal Scientist,

Plasticell Limited

Thomas Kraft

Principal Scientist,

Roche

Thomas Powell

Senior Scientist,

Immunocore

Timothy Hickling

Immunogenicity Expert Scientist,

Roche

Tomasz Witkos

Associate Director,

AstraZeneca

Toria Legh-Land

Computational Pharmaceutics Lead,

Microsol

Trevor Smith

VP Preclinical R&D,

Inovio Pharmaceuticals

Ulrike Rieder

Scientific Lead,

Novartis

Vaios Karanikas

Biomarker Experimental Medicine Leader, Oncology,

Hoffmann La Roche Ltd

Vik Reebye

Head,

MiNA Therapeutics

Vincent Dewar

Head of Immunoassay,

GSK

Vincenzo de Filippis

Associate Professor Biochemistry,

University of Padova

Walter Cabri

Professor,

Fresenius Kabi

Wen Chang

Associate Vice President Discovery and Early Development,

AcuraStem

Will Nesbit

Senior Director - Process Chemistry & CMC,

Bicycle Therapeutics

Wolfgang Koch

Senior Scientist,

F-star Therapeutics Inc

Yann Abraham

Associate Director AI for Single Cell,

Johnson & Johnson Innovative Medicine

Yiping Wu

Senior Scientist,

AstraZeneca

Zahra Rattray

Senior Lecturer,

University of Strathclyde

Zinaida Dedeic

Senior Scientist,

University of Oxford

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Find Out More

Interested in Sponsoring NextGen Biomed?

In-Person Services Digital Marketing Services

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

Advanced Therapies Specialist Team Leader,
Genscript

Biologics 2024 has been one of the best events I have attended so far in my career.

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Impressed by the effort to bring people together.

Business Development Director,

Bioassay

Nice set-up, with good support for exhibitors

Director of Client Relations,

ImmunoPrecise

The start-up zone provides a unique opportunity for you to exhibit, network, and pitch to our global audience of pharma, biotech, and investment professionals.

It's designed for start-ups from across the biologics space, working on cutting-edge therapies, innovative platform technologies, products, and solutions and is an ideal platform to share your business plans and promote your science.

There are two options, based on the type of your organisation with prices starting from £1,500 (+VAT) for companies with own therapeutic research pipeline and registration from £3,500 (+VAT) available for companies offering solutions, services or platform technologies.

For further information and to get started submit the application form below.

The NextGen Biomed Best Poster Presentation Competition & Award includes the best poster presentation award and is intended to honour an outstanding individual performance for a scientific work by either an early career or established scientist, including PhD student and PostDocs.

Please submit your poster presentation by no later than 13^th January 2025 in the below category:

Protein/Antibody Engineering
Bioanalysis & Characterisation
Next Generation Biotherapeutics
Peptides Chemistry & Therapeutics
Oligonucleotides Chemistry & Therapeutics
Sustainable Chemistry & Manufacturing

- Open to all scientists, including students (PhD), PostDocs, and established researchers representing pharma & biotech companies and/or academic institutions
- Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
- ONLY ONE submission per person will be accepted. If authors submit multiple abstracts for consideration for the competition, only one abstract will be taken into consideration

Applicants must follow the procedure as follows:

Register and submit an abstract by 13th January 2025 using the registration link to the right on this page. Please ensure you add the poster display option on the registration page to secure your admission into the Best Poster Competition & Award

Once registered you will be provided with the online abstract submission form

Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.)

The winner with the highest scores will be announced at the Morning Networking Break on Day 3 of the event

The poster presentations will be evaluated by everyone attending the event on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). Attendees will be allowed to cast one vote by selecting their favourite work in the poster area. All votes will be counted at the end of Day 2 at 5pm and results will be announced during the morning networking break on Day 3. .

The winner receiving the highest scores will be announced on Day 3 and will be given a trophy as well as £600 contribution towards travel & accommodation costs to attend the 2026 NextGen Biomed event. Oxford Global will also provide winners with PLUS Pass – 12 months access to our digital content platform providing access to on-demand presentations, exclusive reports and highlights.

Sheraton San Diego Hotel & Marina

1380 Harbor Island Drive, San Diego
California
USA, 92101

By Air

From San Diego International Airport (SAN), the hotel is just 1.5 miles from the airport.

Shuttle: Use the free Sheraton shuttle, available at Terminal 1 & Terminal 2. Look for the “Hotel Courtesy Shuttle” sign.
If Shuttle is unavailable: Take the 992 bus from the airport to the Harbor Island Drive & Sheraton Way stop (5-minute ride). Walk 5 minutes to the hotel.

By Tram/Bus

The total journey from downtown via tram and bus should take around 20-30 minutes.

Take the San Diego Trolley:
Use the Green Line or another line that connects to the Santa Fe Depot station.

Transfer to Bus or Walk:
From Santa Fe Depot, take Bus 992 (Airport Route) toward the San Diego International Airport. Exit at the hotel stop near Harbor Island.

Alternatively, walk approximately 30 minutes (1.5 miles) along Harbor Drive to the hotel.

Ensure to check the trolley and bus schedules for exact timings.

By Car

Directions:

Merge onto I-5 North:

Exit 17A toward W Hawthorn St toward San Diego Airport
Keep left to stay on W Hawthorn St
Turn Right onto N Harbor Drive
Follow N Harbor Drive until you reach Harbor Island Drive
Turn Left onto Harbor Island Drive
Sheraton San Diego Resort will be on your right

Merge onto I-5 South:

Exit 18A toward Sassafras St/San Diego Airport
Turn Right onto W Laurel St
Take a slight right onto N Harbor Drive
Turn Left onto Harbor Island Drive
Sheraton San Diego Resort will be on your right

Parking Options:

Overnight Self-Parking rate has been discounted to $25.00 per vehicle, and Overnight Valet Parking at $65.00 per vehicle.
Event Only Parking is discounted to Self-Parking at $22.00 per vehicle, and Valet Parking at $47.00 per vehicle.

Oxford Global has secured a number of bedrooms at the Sheraton San Diego Hotel & Marina at a reduced conference rate:

Wednesday 1st October 2025 – $309 (inclusive of taxes and fees - no breakfast)
Thursday 2nd October 2025 – $309 (inclusive of taxes and fees - no breakfast)

A nightly resort charge of $15 is included, providing guests with premium amenities:
✔ High-speed Wi-Fi: Available in guest rooms, public areas, meeting spaces, and F&B outlets
✔ Fitness & Recreation: 24-hour fitness centre access, morning yoga class, and 60-minute tennis court use
✔ Airport Shuttle: Complimentary transportation to and from San Diego International Airport

Should you wish to book a room, please email help@oxfordglobal.com

The final cut-off date to book bedrooms is Wednesday 3rd September 2025 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to full cancellation charges.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2025, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery & Development US 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.